Recruiting

Physical Activity Intervention

Sponsor:

Roswell Park Cancer Institute

Code:

NCT06855706

Conditions

Endometrial Carcinoma

Recurrent Fallopian Tube Carcinoma

Recurrent Ovarian Carcinoma

Recurrent Primary Peritoneal Carcinoma

Stage II Fallopian Tube Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Behavioral Intervention

Best Practice

Biospecimen Collection

Electronic Health Record Review

Exercise Intervention

Study Details

Brief summary:

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II- IV ovarian, primary peritoneal, fallopian tube cancer or endometrial cancer that is newly diagnosed. Physical activity is a modifiable risk factor for the prevention and treatment of many diseases. In fact, increased levels of physical activity have been shown to decrease the risk of some cancers as well as increase overall survival in some cancers. Currently, standard of care guidelines include participation in at least 150 minutes of moderate exercise weekly. An automated personalized physical activity intervention may increase physical activity, enhance quality of life, and improve physical function and daily living activities compared to standard recommendations in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer. This trial also evaluates the impact of physical activity on the gut microbiome and immune function. The microbiome is the collection of tiny organisms, like bacteria, that live in and on the body, especially places like the gut. These microorganisms play an important role in health. Information gathered from this study may help understand how the gut microbiome and physical activity influences the immune system in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer.

Conditions

Endometrial Carcinoma

Recurrent Fallopian Tube Carcinoma

Recurrent Ovarian Carcinoma

Recurrent Primary Peritoneal Carcinoma

Stage II Fallopian Tube Cancer AJCC v8

Study ID

NCT06855706

Start date

Jun 4, 2025

Status verified date

Dec, 2025

Completion date

Apr 30, 2028

Anticipated

Primary completion date

Apr 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥ 18 years old on day of signing informed consent
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Participant must satisfy one of the following conditions:

  • Have a clinically suspected or confirmed diagnosis of stage II-IV ovarian, primary peritoneal, or fallopian tube cancer by clinical presentation and elevated CA-125 and may be awaiting staging surgery or tumor tissue biopsy followed by neoadjuvant chemotherapy. Inclusion of clinically suspected ovarian cancer cases is because we want to capture data starting from the earliest point of the diagnostic pathway and before definitive staging surgery. This allows us to assess the impact of physical activity and the feasibility of wearable device monitoring as patients transition into neoadjuvant chemotherapy and potential surgery
  • Have recurrent ovarian, primary peritoneal, or fallopian tube cancer at any time point of their recurrence, if they meet eligibility criteria (any histology accepted). Inclusion of recurrent ovarian cancer cases is because ovarian cancer often recurs, and understanding physical activity patterns and interventions in patients experiencing recurrence is critical for comprehensive insights. This ensures the study includes the continuum of disease management beyond initial diagnosis
  • Have pre-operative biopsy-proven endometrial cancer (endometrioid, serous, mucinous, or clear cell, poorly differentiated) with plans for surgical resection using a minimally invasive approach or medical management with chemotherapy combination, hormonal treatment or radiation. Inclusion of biopsy-proven endometrial cancer cases but not clinically suspected or recurrent cases is because we are focusing on confirmed, newly diagnosed patients who will undergo surgical resection or medical management
  • willing to wear the activity tracking device for at least 70% of their waking hours each day (11 hours/day) throughout the 6-month study period
  • under the care of Roswell Park Comprehensive Cancer Center during the study period, which includes one or more of the following:

  • Receiving cancer treatment at Roswell Park Comprehensive Cancer Center
  • Undergoing surgery at Roswell Park Comprehensive Cancer Center
  • Participating in surveillance visits at Roswell Park Comprehensive Cancer Center
  • Receiving adjuvant treatment at an outside facility but returning to Roswell Park Comprehensive Cancer Center for periodic consultation visits and agreeing to comply with all study procedures, including data sharing from external providers
  • willing to participate in questionnaires and blood and stool collection throughout the study for translational research purposes
  • Participant must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure
  • Have a smartphone with daily internet access that is compatible with the wearable devices and applications used in the study (e.g., Fitbit Sense 2 and CGM applications)

  • NOTE: Patients who are already achieving or exceeding the goal of 150 minutes of physical activity per week are eligible for this study. This inclusion is intentional, as the study aims to evaluate the full spectrum of physical activity levels-both baseline activity and changes over time-and their relationship with clinical outcomes, metabolic measures (e.g., glucose levels), inflammation, and physical function

Exclusion Criteria:

  • serious psychiatric illness that is not currently stabilized, including but not limited to:

  • Schizophrenia or other psychotic disorders
  • Bipolar disorder
  • Sever major depressive disorder
  • Severe personality disorders diagnosed by a qualified mental health professional
  • Recent suicide attempt or psychiatric hospitalization within the previous 12 months
  • Life expectancy of less than 12 months, as determined by the Investigator based on clinical judgment and available prognostic tools
  • history of other invasive malignancies within the last two years, except for:

  • Non-melanoma skin cancer
  • In situ cervical cancer
  • resting heart rate greater than 120 beats per minute after 10 minutes of seated rest, confirmed on two separate measurements
  • systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 100 mmHg, measured after 10 minutes of seated rest, confirmed on two separate measurements
  • Unstable angina or myocardial infarction within the past 3 months.

  • Unstable Angina: Chest pain at rest or chest pain of increasing frequency, severity, or duration that requires medical attention
  • Myocardial Infarction: Heart attack diagnosed by a medical professional
  • Pregnant or nursing participants will be excluded, as confirmed via urine test during screening procedures.
  • unwilling or unable to follow the protocol requirements, including but not limited to:

  • Cognitive impairment that affects the ability to provide informed consent or comply with study procedures
  • Language barriers without access to adequate translation services
  • Lack of access to necessary technology (e.g., smartphones compatible with study devices)
  • Other factors that would prevent adherence to study protocols
  • Any condition which, in the Investigator's opinion, makes the patient unsuitable for participation in the study or may interfere with the patient's ability to comply with the study requirements or the safety of the patient. Conditions may include, but are not limited to:

  • Severe pulmonary disease
  • Uncontrolled metabolic disorders
  • Other significant medical conditions that pose a risk during increased physical activity
  • Participants who do not provide a valid cell phone number or do not consent to receive SMS messages from Fitabase for motivational and compliance monitoring purposes will be excluded from the study.

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Arm I (Personalized Physical Activity intervention)

Patients receive personalized PA goals and positive feedback to increase participation in MVPA in 10-15 minute increments up to 150 minutes per week for 12 weeks then sustain participation for an additional 12 weeks (6 months total). Patients also receive ongoing support to maintain or further increase PA levels up to month 6. Patients wear a Fitbit Sense 2 and CGM device continuously throughout the 6 month intervention. Additionally, patients undergo blood sample collection throughout the study.

active comparator: Arm II (Standard PA)

Patients receive general PA counseling recommending 150 minutes of activity per week consistent with standard of care at time of enrollment. Patients also wear a Fitbit Sense 2 and CGM device for 6 months. Additionally, patients undergo blood sample collection throughout the study.

Interventions

Behavioral Intervention

Receive personalized PA goals and positive feedback

Best Practice

Receive general PA counseling

Biospecimen Collection

Undergo blood sample collection

Electronic Health Record Review

Ancillary studies

Exercise Intervention

Participate in MVPA

Medical Device Usage and Evaluation

Wear a Fitbit Sense 2 and CGM device

Questionnaire Administration

Ancillary studies

Supportive Care

Receive ongoing support

Primary outcome measure

  • Proportion of participants achieving ≥ 150 minutes of moderate to vigorous physical activity (MVPA) per week [ Time Frame: At 3 months (weeks 11 and 12) ]

Central Contacts and Locations

Locations

Roswell Park Cancer Institute

Recruiting

Buffalo, New York, United States, 14263

Contacts

Emese Zsiros

716-845-8337emese.zsiros@roswellpark.org

Principal Investigator:

Emese Zsiros

More Information

Sponsor

Roswell Park Cancer Institute

Last update posted

Jan 6, 2026

Last verified

Dec, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Roswell Park Cancer Institute on 2026-01-06.